2025-04-01 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**0. Key Figures:**

* **Cumulative Return (LLY):** 344.88%
* **Cumulative Return (VOO):** 91.19%
* **Return Difference (LLY vs. VOO):** 253.69%
* **Relative Divergence:** 65.7% (indicating LLY's performance is significantly above the VOO, within the upper 65.7th percentile of historical performance relative to VOO)
* **Current Price:** $821.67
* **Last Market Close:** $814.68 (down $0.95 from previous close)


**1. Company Overview and Performance Comparison:**

Eli Lilly and Co. is a global pharmaceutical company developing and manufacturing medicines and biologics.  LLY's cumulative return significantly outperforms the S&P 500 (VOO) by 253.69 percentage points.  While the relative divergence indicates strong outperformance, it's crucial to remember this is a relative measure against historical data and does not guarantee future performance.

**Alpha and Beta Analysis:**

The provided data shows consistently high CAGR (Compound Annual Growth Rate) for LLY, ranging from 10% to 206% over different periods.  Alpha values are generally positive, suggesting outperformance compared to the benchmark.  Beta values are relatively high, indicating higher volatility than the market.  This high growth and volatility need to be considered alongside risk tolerance.  Note that the relatively low MDD (Maximum Drawdown) in recent years should be taken into account in the context of the generally high volatility implied by the Beta values.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 8.3% | -7.0% | 0.1 | 67.1 |
| 2016-2018  | 47.0% | 8.3% | 41.0% | -0.0 | 94.3 |
| 2017-2019  | 59.0% | 9.8% | 40.0% | 0.3 | 109.5 |
| 2018-2020  | 70.0% | 13.5% | 36.0% | 0.2 | 143.5 |
| 2019-2021  | 118.0% | 13.5% | 45.0% | 0.1 | 238.4 |
| 2020-2022  | 128.0% | 48.4% | 116.0% | 0.1 | 320.0 |
| 2021-2023  | 182.0% | 51.4% | 164.0% | 0.3 | 514.9 |
| 2022-2024  | 206.0% | 55.2% | 183.0% | 0.3 | 686.4 |
| 2023-2025  | 168.0% | 81.8% | 126.0% | 0.2 | 731.8 |


**2. Recent Price Movement:**

* **Closing Price:** $821.67
* **Last Market Price:** $814.68
* **5-day Moving Average:** $840.65
* **20-day Moving Average:** $854.72
* **60-day Moving Average:** $829.67

The stock price is currently below its 5 and 20-day moving averages, suggesting a potential short-term downtrend. However, it's above the 60-day moving average, indicating some longer-term support.  The recent price drop of $0.95 suggests a minor correction.  It is not a significant, sudden drop which might be categorized as a "crash".


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4283 (Medium Risk)
* **RSI:** 37.32 (Suggests the stock is approaching oversold territory, but not yet definitively oversold)
* **PPO:** -0.33 (Negative PPO suggests bearish momentum)
* **20-Day Relative Divergence Change:** -0.7 (Short-term downward trend)
* **Expected Return (vs. S&P 500):** 109.2% over the long term (2+ years)


**4. Recent Earnings Analysis:**

The earnings data shows some volatility.  Note that there are duplicate entries for 2024-10-30. Assuming the first is the correct value, EPS showed strong growth from Q1 2024 to Q2 2024. Q3 2024 showed a noticeable drop. More information is needed to fully analyze this volatility.  Further investigation into the reasons for these fluctuations is recommended.

| Date       | EPS   | Revenue      |
|------------|-------|---------------|
| 2024-10-30 | 1.08  | $11.44 B      |
| 2024-08-08 | 3.29  | $11.30 B      |
| 2024-04-30 | 2.49  | $8.77 B       |
| 2023-11-02 | -0.06 | $9.50 B       |
| 2024-10-30 | -0.06 | $9.50 B       |


**5. Financial Information:**

The financial data shows strong revenue growth and consistently high profit margins.  ROE (Return on Equity) fluctuates, suggesting some variability in profitability, but the numbers remain largely positive.  Further analysis is required to determine the underlying reasons for the ROE fluctuations.


Revenue and Profitability:

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $13.53B | 82.24%       |
| 2024-09-30 | $11.44B | 81.02%       |
| 2024-06-30 | $11.30B | 80.80%       |
| 2024-03-31 | $8.77B  | 80.91%       |
| 2023-12-31 | $9.35B  | 80.88%       |


Capital and Profitability:

| Quarter | Equity   | ROE     |
|---------|----------|---------|
| 2024-12-31 | $14.19B | 31.07%  |
| 2024-09-30 | $14.24B | 6.81%   |
| 2024-06-30 | $13.56B | 21.88%  |
| 2024-03-31 | $12.81B | 17.51%  |
| 2023-12-31 | $10.77B | 20.33%  |


**6. Overall Conclusion:**

LLY exhibits strong historical performance, significantly outperforming the S&P 500.  However, high volatility and recent price corrections warrant caution.  While the expected long-term return is substantial, investors should carefully consider the associated risk.  The recent earnings show some volatility, requiring further investigation.  A deep dive into the causes of the earnings fluctuations and ROE variations is highly recommended before making any investment decisions.  Further analysis considering factors like industry trends and competitive landscape is also crucial for a comprehensive assessment.  The relatively high Beta warrants careful consideration of one's risk tolerance.
